Behind the science

Using AI, ML and data to unlock the mysteries of disease

Our researchers use advanced technology to predict how diseases may progress in certain patients, who is most likely to benefit from a particular treatment or vaccine, and which potential new medicines or vaccines are most likely make a real difference to patient lives.

en-gb
Close Video

Our purpose

We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology

Infectious diseases
1 in 6
deaths globally caused by infectious disease
HIV
39m
people living with HIV globally
Respiratory/Immunology
50yrs
of leading research to help people with respiratory and inflammatory conditions
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide

Behind the science

Discover how we're getting ahead

Test Article 7

hmpv

Test Article 9

Test Article 10

Alternative title test

Test Article 12
Behind the science magazine

Life at GSK

How we help people thrive 

Culture

At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.

The Code     Purpose, strategy and culture

Growth

Helping people grow professionally and personally is fundamental to GSK. Because we know when individuals grow, our company grows too. Everyone at GSK is encouraged to drive their development through a blend of on-the-job experiences, plus best-in-class formal and informal learning.

Life at GSK

Diversity, equity and inclusion

<p>We’re dedicated to diversity, equity and inclusion in what we do and how we do it. Because it's the right thing to do and it helps us perform better. That’s why we focus on recognising and making the most of our differences and encourage everyone to bring their authentic selves to work. We make sure everyone gets equal opportunities and we’re fully committed to ensuring our workforce reflects the communities in which we work.</p>
<p><a data-udi="umb://document/e9f109f2f866472dab2ed3e73b7feef9" href="#" title="Diversity, equity and inclusion" class="button">Diversity, equity and inclusion</a></p>

Wellbeing

We prioritise personal wellbeing so that our people can thrive both in and out of work. We achieve this by fostering a healthy and safe working space for them to succeed and grow. Above all, working at GSK means working with colleagues, friends and managers who support, motivate and care for one another every step of the way.

Life at GSK

pinch icon pinch icon

Positively impacting society and the planet

Access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Global health and health security

We are committed to change the trajectory of high burden diseases in lower-income countries with a focus on prevention and treatment of infectious diseases.

Environment

We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

INVESTORS

We announced our first quarter 2024 results on Wednesday 1 May

en-gb

123

  1. 123